Last updated on May 2018

Gene Therapy for WAS Follow-up

Brief description of study

An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6_hWASP_WPRE (VSVg) lentiviral vector.

Clinical Study Identifier: NCT02333760

Find a site near you

Start Over

UCL Institute of Child Health

London, United Kingdom
  Connect »